OncoMatch/Clinical Trials/NCT07114939
FTT PET/CT in Pancreatic Neuroendocrine Tumors
Is NCT07114939 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies [18F]FluorThanatrace for neuroendocrine carcinoma metastatic.
Treatment: [18F]FluorThanatrace — A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Disease stage
Grade: g1g2g3 (who)
Prior therapy
Cannot have received: liver directed therapy
Exception: patients who have not yet had disease progression after all disease treated
Patients who have received liver directed therapy that treated all of their disease but whom have not yet had disease progression, per medical record review
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Pennsylvania, Perelman Center for Advanced Medicine · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify